Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
94% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PCYC' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» PCYC's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

PCYC Guru Trades in Q3 2014

Jim Simons Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,311,039 sh (-0.09%)
Murray Stahl 7,003 sh (-20.27%)
Ken Fisher 3,244 sh (-36.57%)
» More
Q4 2014

PCYC Guru Trades in Q4 2014

Joel Greenblatt 2,619 sh (New)
Jim Simons 108,000 sh (New)
Ken Fisher 3,264 sh (+0.62%)
PRIMECAP Management 2,310,539 sh (-0.02%)
Murray Stahl 6,401 sh (-8.60%)
» More
Q1 2015

PCYC Guru Trades in Q1 2015

Mario Gabelli 27,750 sh (New)
Louis Moore Bacon 15,000 sh (New)
Eric Mindich 658,020 sh (New)
Paul Tudor Jones 1,951 sh (New)
Jim Simons 331,700 sh (+207.13%)
Joel Greenblatt Sold Out
Ken Fisher Sold Out
PRIMECAP Management 2,284,039 sh (-1.15%)
Murray Stahl 3,305 sh (-48.37%)
» More
Q2 2015

PCYC Guru Trades in Q2 2015

Jim Simons Sold Out
Mario Gabelli Sold Out
PRIMECAP Management Sold Out
Murray Stahl Sold Out
Eric Mindich Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:PY2.Germany,

Pharmacyclics Inc was incorporated in Delaware in 1991 and commenced operations in 1992. It is a biopharmaceutical company, engaged in developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases. On November 13, 2013, the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib, PCI-32765) as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and concurrently on November 13, 2013, the Company commercially launched IMBRUVICATM in the United States. The Company has contracted with a third-party logistics company to warehouse IMBRUVICATM and distribute it to wholesalers, distributors, pharmacies, hospitals, and other drug suppliers that ultimately distribute IMBRUVICATM directly to patients. The Company's competitors include pharmaceutical and biotechnology companies, clinical reference laboratories and government agencies, as well as academic research institutions that are pursuing research activities similar to the company. The FDA and applicable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $816.1
EPS (TTM) $ 0.90
Short Percentage of Float5.88%
52-Week Range $82.51 - 261.68
Shares Outstanding (Mil)76.79

Analyst Estimate

Dec15 Dec16 Dec17
Revenue (Mil $) 1,138 2,028 3,424
EPS ($) 1.06 4.56 10.03
EPS w/o NRI ($) 1.06 4.56 10.03
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for PCYC


Articles On GuruFocus.com
Several Companies Reach 52-Week Highs Sep 20 2016 
Mindich Continues Pattern of Selling More Stakes Than He Buys Sep 15 2015 
PRIMECAP Sells Stake in Biopharmaceutical Company Aug 28 2015 
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015 
AbbVie Floats Mega-Bond Deal For Acquisition Funding May 08 2015 
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
Pharmacyclics Posts A Mixed First Quarter Ahead Of Being Acquired By AbbVie May 07 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly Insider Sells Highlight: PCYC, DIS, AZO, SCI Mar 17 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 

More From Other Websites
Several Companies Reach 52-Week Highs Sep 20 2016
Medivation Is for Sale: How Much Should It Get? May 13 2016
Tax Savvy Execs Work For $1, Get Paid Millions As Capital Gain May 02 2016
Tax Savvy Execs Work For $1, Get Paid Millions As Capital Gain May 02 2016
Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia... Jan 07 2016
Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia... Jan 07 2016
Why AbbVie Should Be Worth 25% More Aug 10 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
The Most Loved Biotechs of Big Hedge Funds May 23 2015
Abbvie specifies breakdown of $21 billion Pharmacyclics deal May 21 2015
Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays May 19 2015
Borrowers warned: Don't be fooled by high grade market resilience May 11 2015
Pharmacyclics tops 1Q profit forecasts May 01 2015
Biz Break: The 2015 SV150: Apple in command, Wall Street has demands Apr 24 2015
Pharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge... Apr 02 2015
Pharmacyclics cancer drug successful as combination therapy - independent panel Mar 16 2015
FDA panel recommends unblinding study after Imbruvica shows clear benefit Mar 16 2015
Biz Break: Pharmacyclics cofounder on $21B buyout -- 'This is a company that kept fighting' Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)